Equities

Orchestra Biomed Holdings Inc

OBIO:NMQ

Orchestra Biomed Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.57
  • Today's Change0.13 / 1.75%
  • Shares traded51.24k
  • 1 Year change+14.52%
  • Beta0.4433
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Orchestra BioMed Holdings, Inc. is a biomedical innovation company. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. It is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. It is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

  • Revenue in USD (TTM)2.22m
  • Net income in USD-51.64m
  • Incorporated2023
  • Employees56.00
  • Location
    Orchestra Biomed Holdings Inc150 Union Square DriveNEW HOPE 18938United StatesUSA
  • Phone+1 (646) 343-9298
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cibus Inc2.32m-285.67m213.83m183.00--0.6345--92.17-18.29-18.290.152213.240.0084----12,677.60-129.84-86.28-147.90-96.45-----15,483.49-792.07---3.170.0039--1,057.3350.41-1,484.44--18.53--
Delcath Systems Inc4.61m-49.79m219.79m76.00--13.76--47.71-2.65-2.650.23570.57470.13820.45454.5660,618.42-149.30-116.57-249.28-243.2170.5471.02-1,080.73-1,235.372.25-42.250.3348---24.05-9.53-30.60---5.26--
AngioDynamics, Inc.324.01m-192.37m227.51m815.00--1.05--0.7022-4.78-4.788.105.410.74682.666.46397,555.80-44.34-9.12-54.02-10.1750.1754.23-59.37-19.481.62--0.00--7.135.30-97.54--3.55--
Semler Scientific Inc65.88m21.69m230.56m92.0011.742.9010.323.502.782.788.4511.260.85515.138.51716,097.8028.1438.8331.1444.4189.4390.2232.9232.5812.11--0.00--20.2825.9843.6932.64-0.3821--
Utah Medical Products, Inc.49.04m16.38m234.22m169.0014.721.8610.844.784.514.5113.5035.600.37272.0913.24290,201.2012.4412.6913.0213.1959.0561.5733.3930.5117.89--0.0037.05-3.933.640.98341.659.711.86
Pulmonx Corp72.99m-58.73m244.54m279.00--2.21--3.35-1.54-1.541.912.850.3991.147.81261,627.20-32.11-26.27-35.87-28.9774.3171.95-80.46-93.766.14--0.252--27.9827.98-3.26--20.62--
CVRx Inc42.09m-52.01m253.75m200.00--3.83--6.03-2.48-2.482.013.070.36780.67815.64210,430.00-45.45---48.95--84.45---123.58--10.87-21.110.3064--74.89--0.5528------
Atlantic International Corp0.00-5.00m268.01m7.00---------13.49-13.490.00-1.100.00----0.00-84.66-71.97-128.28-106.09--61.01---1,471.82----1.40---100.00---37.43------
Orchestra Biomed Holdings Inc2.22m-51.64m270.92m56.00--4.74--122.26-1.47-1.470.0631.600.02031.0130.9939,571.43-47.18---52.58--92.06---2,330.46--7.33--0.00---21.88---37.91------
Tactile Systems Technology Inc276.67m28.19m271.60m992.009.661.407.820.98171.181.1811.708.141.016.776.05278,896.2010.300.901512.181.0949.9849.1010.190.83093.63--0.1280.0011.2013.81259.6033.91-23.62--
Zynex Inc188.68m8.17m283.43m1.10k39.458.7322.411.500.22610.22615.391.021.592.526.56171,530.006.8914.588.4117.5280.2279.624.3310.442.877.240.6381--16.5442.01-42.910.37412.19--
LifeMD Inc163.56m-26.46m287.99m207.00------1.76-0.7458-0.74584.57-0.02083.436.7039.54790,168.80-44.16-153.05-195.60-526.9188.2183.66-12.87-45.440.9409-6.340.9332--28.1578.9051.27--143.64--
OraSure Technologies, Inc.304.64m22.85m298.06m638.0013.260.69936.960.97840.3040.3044.115.760.65732.774.31477,493.704.930.72385.420.821245.2646.947.501.1310.49--0.00170.004.6417.41413.1782.2010.18--
Nevro Corp430.75m-82.59m307.79m1.22k--1.10--0.7145-2.28-2.2811.907.590.7361.146.04354,523.50-14.11-13.64-16.06-16.6868.9468.54-19.17-20.675.57--0.4354--4.631.88-3,172.74--0.9012--
Sight Sciences Inc81.50m-54.75m307.99m214.00--2.81--3.78-1.12-1.121.672.200.46281.665.09380,822.40-31.09-38.78-33.65-42.2085.7380.74-67.18-105.1412.42-14.760.2358--13.6360.8435.59--6.77--
Cerus Corp191.72m-31.56m318.01m288.00--6.44--1.66-0.1742-0.17421.060.26710.96231.928.03665,680.60-15.91-25.99-24.20-40.6261.7361.90-16.53-35.811.72-2.160.6287---0.806119.6912.37--32.07--
Data as of Jul 03 2024. Currency figures normalised to Orchestra Biomed Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

34.45%Per cent of shares held by top holders
HolderShares% Held
RTW Investments LPas of 31 Mar 20245.62m15.71%
Perceptive Advisors LLCas of 31 Mar 20242.55m7.11%
The Vanguard Group, Inc.as of 31 Mar 20241.19m3.34%
BlackRock Fund Advisorsas of 31 Mar 2024851.84k2.38%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024558.82k1.56%
BlackRock Advisors LLCas of 31 Mar 2024542.08k1.52%
Geode Capital Management LLCas of 31 Mar 2024440.10k1.23%
SSgA Funds Management, Inc.as of 31 Mar 2024254.95k0.71%
Charles Schwab Investment Management, Inc.as of 31 Mar 2024179.71k0.50%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024140.04k0.39%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.